Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Spinal cord injury
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatSpinal cord injuryContusionSprague-Dawley (Charles River)femalen = Moderate injury: DMSO control 6, NSC 7, NSC plus curcumin 6…Curcumin high dose by percutaneous intramuscular injection at or near the injury site; low dose curcumin intraperitoneally; neural stem cells by direct microinjection into the injured cord, 1 mm deep at the contusion site over ten minutes via a 30-gauge needleCurcumin high dose 60 mg/ml/kg body weight in DMSO; curcumi…Curcumin or DMSO within 30 minutes of contusion; stem cell transplantation one…
Model: Spinal cord contusion after aseptic T9-T10 laminectomy using a weight-drop apparatus, a guided 10 g rod dropped 12.5 mm (moderate) or 25 mm (severe) onto exposed dura mater
In moderate injury, neural stem cells alone improved BBB score from week three (12.86 +/- 0.93 versus 9.67 +/- 1.02 at week six, p = 0.029) and adding high dose curcumin gave no additional benefit. In severe injury, either therapy alone gave only transient week two improvement, whereas the combinat…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.